Objective: Short term 24hour brachial blood pressure (BP) variability (24hbBPV) has emerged as an indicator of hypertension-mediated organ damage (HMOD) and a predictor of cardiovascular disease (CVD) events in highrisk populations. At the same time, the clinical significance of short term central BPV (24hcBPV) remains under investigation. To our knowledge, no study so far has assessed 24hbBPV and 24hcBPV in patients with psoriasis, who are characterized by subclinical chronic inflammation and increased CVD risk. Design and method: Patients with psoriasis and non-psoriasis individuals were recruited in the absence of diabetes and established CVD. 24h ambulatory BP was measured with the Mobil-O-Graph device. Both 24hbBPV and 24hcBPV during the whole 24h and the respective daytime and nighttime periods were extracted from the relevant ambulatory BP profiles. More specifically, in-house software was applied for the automated calculation of brachial and central average real variability (bARV/cARV) of systolic/diastolic BP (SBP/DBP), and the weighted standard deviation (wSD) of 24h SBP as a classic BPV index, using raw ambulatory BP monitoring data. Results: A total of 114 participants were studied (mean age 49.7 ± 12.1years; 39.5% females; 21.9% hypertensives). Patients with psoriasis (n = 74) did not significantly differ compared to controls (n = 40) in terms of age, sex, office BP, hypertension prevalence, and body mass index. Comparison of brachial and central 24hBP measurements showed lower 24h and nighttime brachial and central DBP in the psoriasis group compared to controls, but similar SBP values in the respective periods (Table 1a). By contrast, both bARV and cARV of 24h and daytime SBP, as well as bARV and cARV of 24h and daytime DBP, were significantly elevated in psoriasis patients (Table 1b). Conclusions: This is the first study reporting increased 24h BPV of both brachial and central SBP/DBP in patients with psoriasis. Whether 24hbBPV and 24hcBPV may be used as a subtle marker of preclinical HMOD warrants further investigation in patients with chronic immune-mediated inflammation.